Prothymosin a (PTa) is a small highly acidic protein found in the nuclei of virtually all mammalian tissues. Its high conservation in mammals and wide tissue distribution suggest an essential biological role. While the exact mechanism of action of PTa remains elusive, the one constant has been its relationship with the proliferative state of the cell and its requirement for cellular growth and survival. Recently PTa was found to promote transcriptional activity by sequestering the anticoactivator, REA from the Estrogen Receptor (ER) complex. We now report that Estradiol (E 2 ) upregulates PTa mRNA and protein expression. Further studies indicate that ERa regulates PTa gene transcriptional activity. We have also delimited the region of PTa gene promoter involved in ERa-mediated transcriptional regulation and identified a novel ERabinding element. Increased intracellular PTa expression in the presence of estrogens is accompanied by increased nuclear/decreased cytoplasmic localization. Increased nuclear expression of PTa is correlated with increased proliferation as measured by expression of Ki67 nuclear antigen. Conversely, inhibition of nuclear PTa expression in breast cancer cells using antisense methodology resulted in the inhibition of E 2 -induced breast cancer cell proliferation. Overall these studies underscore the importance of PTa in estrogen-induced breast cell proliferation.
Introduction
The estrogen receptor (ER) protein is essential for mediating the actions of estrogen in target tissues. The binding of estrogen initiates a process of receptor activation that includes the high affinity binding of ER to specific DNA sequences, termed estrogen response elements (EREs). The interaction of ER with EREs results in the modulation of specific gene expression, through which the physiological actions of estrogens are manifested (reviewed in Aranda and Pascual, 2001) . Estrogens acting via the ER dramatically escalate proliferative and metastatic activity in breast tumor cells, in part via the induction of growth factors, proteases, and basement membrane receptors (reviewed in Russo and Russo, 1998) . However, the relative role of the induction of these genes on the proliferative effects of estrogens in breast cancer cells is not welldefined.
Prothymosin a (PTa) is a small highly acidic protein found in the nuclei of virtually all mammalian tissues (Clinton et al., 1991; Gomez-Marquez and Segade, 1988; Goodall et al., 1986; Manrow et al., 1991; Palvimo and Linnala-Kannkunen, 1990; Watts et al., 1989) . Its high conservation in mammals and wide tissue distribution suggest an essential biological role. PTa expression correlates well with the proliferative activity of tissues (Eschenfeldt and Berger, 1986; Gomez-Marquez et al., 1989; Rodriguez et al., 1998; Sburlati et al., 1991; Wu et al., 1997) . Recently, PTa was shown to be capable of transforming rodent fibroblast cells in a manner similar to Ras, suggesting that PTa may be an important downstream target for inducers of cellular transformation (Orre et al., 2001) . In breast cancer PTa appears to have some prognostic value. PTa expression is higher in tumor samples than in normal breast tissue (Tsitsilonis et al., 1998) , and the expression levels of PTa can be correlated with the proliferation status and metastatic potential of tumors (Magdalena et al., 2000; Tsitsilonis et al., 1998) .
While PTa appears to play a role in cell proliferation, PTa also has an emerging role in the regulation of transcription. Recently Martini et al. (2000) reported that PTa is involved in the transcriptional repression by the anticoactivator factor, Repressor of Estrogen Receptor Activity (REA). PTa is able to promote ER transcriptional activity by sequestering REA from the ER complex. In addition the PTa protein has been localized in the nucleus (Clinton et al., 1991; Manrow et al., 1991; Palvimo and Linnala-Kannkunen, 1990; Wu et al., 1997) and studies suggest that PTa binds specifically to linker histone H1 and cooperates in nucleosome assembly (Diaz-Jullien et al., 1996; Gomez-Marquez and Rodriguez, 1998; Karetsou et al., 1998) , implicating a putative nuclear function related to chromatin remodeling. A role for PTa in the transcriptional activation process is supported by studies wherein cells overexpressing PTa exhibit more active chromatin and higher rates of transcriptional activity than control cells (Karetsou et al., 1998) .
The intracellular signaling pathways governing PTa expression are not well-defined. PTa mRNA levels are increased after serum restitution or after stimulation with various mitogens (Pineiro et al., 2000; Zalvide et al., 1992) . Thus far, only two transcription factors have been proposed to positively regulate the PTa gene promoter, E2F (Eilers et al., 1991; Szabo et al., 1993) and c-myc (Desbarats et al., 1996; Gaubatz et al., 1994) . PTa expression has been proposed to be under the direct control of c-myc through a DNA element known as the E-box, however other findings do not confirm this observation (Mol et al., 1995) . Studies indicate that c-myc expression is not necessary for PTa expression (Loidi et al., 1999) . It has been reported that the transcription factor elongation factor (E2F) which is involved in the regulation of genes important in DNA replication and cell cycle regulation also activates PTa gene transcriptional activity (Eilers et al., 1991; Szabo et al., 1993) . PTa has also been reported to be negatively regulated by p53, further supporting its potential role in proliferation of the cell (Zhao et al., 2000) . The PTa protein is phosphorylated although the physiological relevance of this finding is not known (Perez-Estevez et al., 1997; Sburlati et al., 1993) .
We report that estrogens upreglate PTa mRNA and protein levels in breast cancer cells. Estradiol upregulates PTa gene transcription and we have delimited a novel region involved in this transcriptional activation. Our results indicate that ERa is part of the transcriptional complex that binds to PTa gene promoter and suggest direct transcriptional regulation of this gene by ERa. PTa induction by estrogens appears to be involved in estrogen induction of breast cancer cell proliferation. Figure 1a (left panel) is a Northern blot using the human PTa cDNA as a probe. We found that PTa 1.4 kb mRNA is present at 2 -3-fold higher levels in estradiol (E 2 )-treated cells when compared to control cells 24 h after treatment. No increase in PTa mRNA was observed in the presence of the antiestrogen ICI182,780 (ICI). Upregulation of PTa by E 2 was evident even with cycloheximide pretreatment, suggesting that intervening protein synthesis is not required. The increase is PTa mRNA in response to estrogens is reflected at the protein level wherein we also observe a 2 -3-fold increase ( Figure 1a , right panel).
Results

Identification of PTa as an estrogen-regulated gene
Shown in
Induction of Prothymosin a gene transcriptional activity by estrogens
To determine if estrogen regulation of PTa expression occurs at the transcriptional level a reporter construct containing the 5' regulatory region of the PTa gene, pPstI PTa CAT (Figure 1b) (Szabo et al., 1993) (Mol et al., 1995) , was transfected into an ER positive breast cancer cell line MCF7 (Figure 1c ). After introduction of pPstI PTa CAT, cells were treated with increasing concentrations of E 2 and the antiestrogen transhydroxytamoxifen (TOT). Analyses of reporter activity reveal a dose dependent increase in PTa gene transcriptional activity in response to E 2 but not TOT (Figure 1c) .
The role of ERa in the transcriptional regulation of the PTa gene was examined in two ERa negative cell lines transfected with an expression vector for wild type ERa. A significant increase in transcriptional activity of the pPstI PTa CAT reporter construct in the presence of estradiol (E 2 ) was observed in human breast cancer MDA-MB-231 cells when cells were cotransfected with an expression vector for ERa (Figure 2a) . A slightly higher activation of PTa gene transcriptional activity by estrogens was evident in Hec-1B human endometrial cancer cells when compared to MDA-MB-231 cells. TOT did not activate transcription from the PTa gene reporter construct in any of these cell lines. No increase in the activity of the control pCAT3 promoter vector was observed with E 2 or TOT (Figure 2a ).
Identification of PTa gene promoter regions required for activation by estrogens
To determine the promoter region(s) involved in estrogen activation of PTa gene transcriptional activation, a reporter construct containing the 5' regulatory region of the PTa gene from the ApaI site located 70.819 kb from the transcriptional start site, pApaI PTa CAT, was introduced into MCF7, MDA-MB-231, and Hec-1B cells. Specifically we wanted to determine if the E-box located at 71.173 kb of the PTa gene promoter was required for E 2 -induced increase in PTa gene transcriptional activity (Figure 1b) . Our results indicate that E 2 induced an increase in pApaI PTa CAT activity and the region between 75 and 70.819 kb of the human PTa gene is not required for transcriptional induction by E 2 (Figure 2b ). Note that there were no differences in the basal activities of the pPstI PTa CAT and pApaI PTa CAT constructs (data not shown). Similar observations were made in the three cell lines examined. These results suggest that the induction of PTa gene transcriptional activity by E 2 is not mediated through the E-box in the 75 kb promoter region of the PTa gene. Thus it is unlikely that estrogen-stimulated increase in PTa expression is exerted through increased expression of c-myc in response to estrogens (Dubik and Shiu, 1988 ) and binding of c-myc to the E-box in this region. Cells transfected with the empty control pCMV vector (lacking the ERa cDNA) did not show an E 2 -mediated increase in pApaI PTa CAT activity (Figure 2b ). The antiestrogen TOT blocked E 2 -mediated induction of both reporters (Figure 2c ). These findings suggest a requirement for the ERa in E 2 -mediated transcriptional activation of PTa gene activity.
Deletional analyses of the 819 bp region was performed to further delimit the region of the PTa promoter required for ERa transcriptional activation.
These experiments were conducted in Hec-1B endometrial carcinoma cells wherein we observe the highest activation from the pPstI PTa CAT reporter construct estradiol (E 2 , 10 78 M), E 2 (10 78 M)+CHX pretreatment, or ICI 182,780 (ICI, 10 77 M) as indicated. Equal amounts (20 mg) of total RNA were separated by electrophoresis. The blot was probed with the random primer labeled PTa cDNA. As an RNA loading control, the same blot was reprobed with 36B4 cDNA. Right panel: Western blot analyses of PTa protein levels in MCF7 cells in the absence (C) or presence of E 2 . Whole cell lysates were collected 24 h after treatment, electrophoresed on SDS -PAGE gels, transferred to nitrocellulose filters, probed with PTa polyclonal antibody, and visualized using horseradish peroxidase-conjugated secondary antibody. The lower figure shows the Ponceau S-stained blot to show equal loading. The autoradiographs shown in (a) are representative of three separate experiments. (b) The PTa gene promoter region (c) MCF7 cells were transfected with the PTa gene reporter construct, PstI PTa CAT, along with a b-galactosidase internal control reporter to correct for transfection efficiency. Cells were then treated for 24 h with control ethanol vehicle (C) or varying concentrations of E 2 and TOT as indicated. Cell extracts were prepared and analysed for CAT activity and b-galactosidase activity. Values are the means+s.e. among the three cell lines examined. Using several pApaI PTa CAT deletion mutants we identified a 260 bp fragment flanked by the SalI (7722 bp) and SmaI (7460 bp) sites as important for estrogen induction of PTa promoter activity ( Figure 3a ). While deletion of the XhoI/SalI fragment significantly increased basal reporter activity, E 2 was still able to induce reporter activity about fourfold over basal activity. When the fragment encompassed by SalI/ SmaI was broken into two parts, SalI/SmaI (70.72/ 70.59 kb) SmaI/SmaI (70.59/70.46 kb), and introduced into the pCAT3 promoter vector, E 2 -induced CAT reporter activity only in the SalI/SmaI (70.72/ 70.59 kb) fragment (Figure 3b ). The fold-induction from the pSalI/SmaI PTa CAT cannot be attributed to change in basal activity as this parameter was not significantly different among the pPstI PTa CAT, pApaI PTa CAT, and pSalI/SmaI PTa CAT reporter constructs.
The SalI/SmaI (70.72/70.59 kb) region of the PTa gene was divided into three 43 bp fragments and oligonucleotides were synthesized corresponding to these fragments. Oligonucleotides were cloned into the pCAT3 reporter vector upstream of the heterologous SV40 promoter. The reporter constructs were transfected into Hec-1B cells along with an expression vector for ERa. Similar fold-inductions with E 2 were observed with the (7679/7637)-PTa CAT reporter constructs as that observed with the pPstI PTa CAT reporter ( Figure 3b ). No significant induction over basal activity by E 2 was evident with reporter constructs containing the other two fragments, 7722/7680 and 7636/7594. Of note, there were no differences in basal activity between the SalI/SmaI fragment and each of the 43 bp fragments it contains.
Sequence analysis of the 7679/7637 fragment indicates no consensus sequence for binding sites for any known transcription factors except for an incomplete half-ERE at 7677 to 7672 (Figure 3c ). While there are reports of ER binding to half-EREs, there are also reports of binding of other transcription factors to the half-ERE that results in the regulation of ER-mediated gene transcription (Chen et al., 1998; Garnier et al., 1997; Klinge et al., 1997) . Also of interest are three repeats of a TGCCC element in this region, one next to the half-ERE and two sequentially ordered at the 3' end ( Figure 3c ). To analyse the role of the incomplete half-ERE, these six residues were mutated, introduced into the pCAT3 vector (mut 1) and transfected into Hec-1B cells along with an expression vector for ERa. In these experiments we observe no activation of reporter activity upon mutation of the half-ERE (Figure 3c ). Mutations introduced 7659 to 7639 (mut 3, 4 and 5) also disrupted E 2 fold-induction. The magnitude of response to estrogens did not change with mut 2, however a significant decrease in basal activity was observed resulting in a higher fold-induction relative to wild type PTa 7679/7637 fragment. Our mutational analyses also indicate that the two TGCCC elements at the 3' end are important for estrogen activation.
To further verify the importance of this novel estrogen response element, we introduced mutations 1 and 5 into the context of the natural PTa ApaI promoter. This would allow us to better assess the physiological relevance of this element on the natural promoter. When pApaI PTa pCAT (mut 1) and pApaI PTa pCAT (mut 5) were transfected into Hec-1B cells, the E 2 responsiveness was completely blocked with mut 5 but not mut 1 (Figure 3d ). Thus the 3' end of the PTa 7679/7637 fragment is important for estrogen activation. While the incomplete half-ERE may be important for transcriptional activation in the context of a heterologous SV40 promoter, it does not appear to be necessary in the context of the natural promoter.
Identification of ERa functional domains involved in activation of PTa gene transcription
Further insight into the mechanism of ERa regulation of PTa gene transcriptional activation can be obtained from studies identifying the functional domains of the ERa required for PTa gene transcriptional activation. We examined the ability of ERa mutants with impaired activation function, hormone binding ability, or DNA binding ability to activate PTa gene reporter constructs. These experiments were conducted in Hec-1B cells where low levels of endogenous ERa allowed us to assess mutant ERa function. No activation of the (7679/7637)-PTa CAT reporter construct was observed with expression vectors for ERa with mutations in the DNA binding domain and AF2 region (Figure 4 ). ERa with three mutations in the DNA binding domain (HE82) that converts DNA binding specificity from an ERE to Glucocorticoid Receptor Response Element (GRE) (Mader et al., 1989) did not induce enhancer activity. However deletion of the A/B domain, which has been shown to disrupt Activation Function 1 (AF-1) of the ER (Ali et al., 1993) did not significantly affect the ability of ERa to mediate activation of the PTa gene promoter reporter construct. Our data suggest that the DNA binding and AF2 domains, but not the AF1 region, are required for transcriptional activation of PTa gene.
Biochemical analyses of interactions of MCF7 breast cancer cell factors with the Prothymosin a gene promoter region
Gel shift assays were then conducted to dissect the DNA-protein complex(es) that occur within the 43 bp region that mediate ERa regulation.
32 P end-labeled (7679/7637)-PTa oligonucleotides were incubated with purified recombinant ERa. A representative autoradiograph is shown in Figure 5 and indicates the presence of one major DNA-protein complex as a shifted band (SB). The specificity of the DNA-protein interactions was verified using competitive gel shift assays with unlabeled (7679/7637)-PTa oligonucleotide. The DNA-protein complex was supershifted by ERa antibody and could be competed off by unlabeled consensus ERE. Thus estrogen transcriptional activation appears to be mediated through ERa binding to PTa gene promoter elements. However, ERa binding to the PTa promoter element is much weaker than ERa binding to the ERE ( Figure 5, lanes 11 -12) . Further studies were conducted to determine the binding sites for ERa. Gel shift analyses indicate that ERa binding is disrupted upon mutations at 659/7653 (mut 3) and a TGCCC element at 7645/7640 (mut 5) ( Figure 5 ). These results are consistent with the involvement of these regions in ERa-mediated transcriptional activation. Mutation of the half-ERE at 7677/672 did not disrupt ERa binding which is consistent with our observation that this element is not necessary for ERa activation in the context of the natural promoter. Mut 4, while not affecting ERa binding, is associated with decreased ERa-mediated activation. It is likely that this site may bind to accessory factors required for ERa-mediated activation.
Determination of the relevance of ERa regulation of PTa transcriptional activity on breast cancer growth
We then determined if estrogen-induced PTa expression can be correlated with increased proliferation. For these studies we used immunofluorescence staining to determine if the same cells that express PTa are also proliferating. PTa has been proposed to move between nuclear and cytoplasmic compartments (Enkemann et al., 2000) . However the relative importance of nuclear and cytoplasmic localization on its proliferative effects has not been examined. We used expression of Ki67 as a measure of proliferation status of the cells as well as a control for nuclear staining (Iatropaulos and Williams, 1996) . Twenty-four hours after treatment, we see an increase in the number of cells that show primary nuclear (and decreased cytoplasmic) localization of PTa in the presence of estrogens, which was decreased when antiestrogen ICI182,780 was added (Figure 6a ). Ki67 staining is highest in cells wherein PTa is primarily nuclear.
A self-contained tetracycline-regulated retroviral vector system (Paulus et al., 1996) was used to express antisense PTa (PTa AS ). In the presence of tetracycline, expression of PTa AS is inhibited. An ensuing 25+7% and 48+10% decrease in PTa expression in control and E 2 treated cells, respectively, was observed in MCF7 cells after infection with PTa AS retroviruses (Figure 6b ). Infection with PTa AS retroviruses decreased PTa nuclear staining and Ki67 expression normally observed 24 h after treatment with E 2 . To confirm this, we also used a proliferation assay. While control cells show the expected increase in cell number after 6 days treatment with E 2 , cells infected with PTa AS retroviruses showed no increase in proliferation in the presence of E 2 (Figure 6c ). These findings suggest that induction of PTa expression by E 2 plays a role in E 2 -mediated breast cancer growth induction.
Discussion
In summary, we have shown estrogen-stimulated gene transcription from PTa gene promoter-containing reporter constructs. We have delimited the region required for estrogen-mediated induction to a 43 bp fragment, and the mechanism for ERa-mediated activation most likely involves a complex interplay between ERa and other protein factors bound to this region. The transcriptional activation by estrogens appears to involve ERa binding to the PTa gene promoter. Estrogen treatment also resulted in increased PTa nuclear localization which in turn is correlated with increased cell proliferation. Our studies also indicate that PTa plays a role in E 2 -induced proliferation of breast cancer cells.
We observed PTa to be a gene upregulated in E 2 -treated cells using Northern blot analyses. This increase was not observed with the antiestrogen TOT. Similarly Garnier et al., using differential display report that PTa mRNA expression was also enhanced in neuroblastoma cells after estrogen treatment (Garnier et al., 1997) . The present studies now show that the increase in PTa mRNA in the presence of E 2 is also evident at the protein level. This protein has been of considerable interest to us due to its role in cellular proliferation. It is a highly acidic nuclear protein widely expressed in all cell types. While the exact mechanism of action of PTa remains elusive, the one constant has been its requirement for cellular growth and survival (Eschenfeldt and Berger, 1986; Gomez-Marquez et al., 1989; Rodriguez et al., 1998; Sburlati et al., 1991; Wu et al., 1997) . Recently, PTa was shown to be capable of transforming rodent fibroblast cells in a manner similar to Ras, suggesting that PTa may be an important downstream target for inducers of cellular transformation (Orre et al., 2001) . PTa can serve as a marker for both breast cancer and hepatocarcinomas, and several malignant tissues have increased levels of PTa (Magdalena et al., 2000; Pineiro et al., 2000; Tsitsilonis et al., 1998) . Another source of interest for us is that PTa has also been shown to enhance ER transcriptional activity (Martini et al., 2000) , further validating its connection to estrogens.
Regarding the transcriptional regulation of PTa, there are still many unanswered questions. PTa mRNA levels are increased after serum restitution or after stimulation with various mitogens, further supporting its role in the cell cycle (Pineiro et al., 2000; Zalvide et al., 1992) . However, levels of PTa do not vary significantly during the cell cycle making it hard to assign it to a particular cellular process (Pineiro et al., 2000) . While there is an E2F binding site between 7323 and 7316, the role of this site in E2F-induction of PTa gene transcriptional regulation has not been specifically tested (Eilers et al., 1991; Szabo et al., 1993) . Our results suggest that this site is not necessary for ERa regulation. While the E-box at 71.173 kb of the PTa gene promoter has been proposed to mediate c-myc induction, c-myc activation of PTa expression has been put into doubt (Desbarats et al., 1996; Gaubatz et al., 1994; Mol et al., 1995) . Studies with antisense c-myc suggest that PTa expression is not completely dependent on c-myc. While c-myc is a wellknown ER target gene (Dubik and Shiu, 1988 ) the present studies indicate that it is unlikely that E 2 upregulation of PTa occurs indirectly through E 2 -mediated induction of c-myc expression. Our studies suggest that intervening protein synthesis is not required for the increase in PTa mRNA expression in the presence of E 2 . Moreover, deletion of the E-box did not affect E 2 -mediated upregulation of PTa gene transcriptional activity. Another group has shown that E 2 does not regulate the expression of N-myc, the neural counterpart of c-myc in neural cells, wherein E 2 has been demonstrated to upregulate PTa expression (Garnier et al., 1997) . Additional supporting evidence for direct transcriptional regulation of the PTa gene by the ER is that the increase in PTa expression was observed 1 h after estrogen treatment in neuroblastoma cells (Garnier et al., 1997) .
While there are no full EREs for binding of the ERa in the PTa promoter, there are several half-palindromic EREs that may be able to promote transcription (Chen et al., 1998; Klinge et al., 1997) . However, the incomplete half-ERE (AGGTCG) in the 43 bp region does not appear to be essential for ERa regulation of PTa gene promoter or for ERa binding. The 3' end of the 43 bp region important for ERa transcriptional activation and binding does contain a direct TGCCC (or GCCCT) repeat. Since a GCCCT direct repeat has been shown to bind Sp1 (Dennig et al., 1995) and Sp1 can interact with ERa to transactivate genes (Safe, 2001) , we investigated the possibility that this element may recruit ERa through Sp1 interaction. However, gel shift analysis revealed no binding of Sp1 to this element or significant effects on ERa activation (data not shown).
During the preparation of this manuscript, there was a report from another group examining the regulation of PTa by estrogens (Martini and Katzenellenbogen, 2001) . Their studies indicate the involvement of two half-EREs in the regulation by estrogens. These halfEREs, located at 7886 to 7861 and 7588 to 7560, were also proposed (but not examined) by Garnier et al. (1997) to be involved in estrogen regulation of PTa expression in neuroblastoma cells. While mutational analyses support the involvement of these two halfEREs (Martini and Katzenellenbogen, 2001) , the halfEREs were not cloned upstream of a heterologous promoter to indicate enhancer activity. Our results indicate that when the SmaI/SmaI region (containing the half-EREs at 7588 to 7560) was cloned upstream of a heterologous promoter no E 2 -mediated activation was evident. In addition when the half-ERE at 7886 to 7861 was deleted (compare ApaI PTa CAT with PstI PTa CAT) we did not see a significant decrease in E 2 -mediated activation. Thus the decrease in promoter activity resulting from mutation of the two half-EREs may be attributed to disruption of intermolecular interactions in the promoter region, rather than promoter context-independent transcriptional regulation. The differences between these two reports may be also attributed to methodological differences.
Overall our findings reveal an interesting cross-talk between ERa and PTa. As mentioned above it has been shown that PTa can influence ER transcriptional activity (Martini et al., 2000) . PTa does not directly interact with ER but appears to sequester the anticoactivator factor REA from the ER transcriptional complex. ER is then able to interact with its coactivators. Certain aspects of PTa structure may be useful in understanding the transcriptional regulatory function of PTa. Because of the high acidity of the protein (Palvimo and Linnala-Kankkunen, 1990 ) it is unlikely to be a DNA binding protein. There are structural similarities between PTa and nuclear proteins known to be involved in chromatin activity, and it has been reported that PTa interacts specifically with histone H1 (Diaz-Jullien et al., 1996; GomezMarquez and Rodriguez, 1998; Karetsou et al., 1998) . PTa is proposed to play a role in nucleosome assembly (Diaz-Jullien et al., 1996; Gomez-Marquez and Rodriguez, 1998; Karetsou et al., 1998) , implicating a putative nuclear function related to chromatin remodeling. Transcriptional studies suggest a role for histone H1 in the high compactation of DNA and hence the general repression of transcription; other studies suggest H1 to be involved in the transcriptional repression of a selected group of genes (reviewed in Crane-Robinson, 1999; Wolfe et al., 1997) PTa may play a role in transcriptional activation by associating with histone H1 and releasing histone H1 from chromatin. By functioning as a histone receptor (histone sink), PTa may allow access of the basal transcription factors to the DNA template. Regardless of the exact mechanism of PTa regulation of ER transcriptional activity, the regulation of PTa expression by E 2 adds another level of complexity and may represent a positive feedback loop for E 2 -ERa regulation of transcription.
Our studies suggest that estrogens may be involved in the regulation of PTa localization. While the localization of PTa have been initially reported to be primarily nuclear, more recent reports also indicate cytoplasmic localization. However, none of these studies have compared PTa localization in the absence and presence of mitogenic agents. We observe an increase in PTa nuclear localization in the presence of estrogens which translates to increased cell proliferation. Conversely, infection with PTa AS retroviruses results in decreased estrogen-induced nuclear PTa localization and decreased cell proliferation. These findings also suggest that the increase in PTa protein expression in the nucleus may be attributed to the transcriptional effects of estrogen on PTa gene transcription.
While the exact details of the mechanism of action of PTa remain elusive, it is clearly involved in the regulation of cell transformation and proliferation. The estrogen receptor (ER) is a ligand activated transcription factor and the identification of 'primary' ER target genes is imperative for understanding the basis for the proliferative action of ER in breast cancer cells. There are only a few candidate genes that appear to be under the direct regulation of the ER; much less genes that are associated with cell proliferative activity. PTa is a particularly strong candidate because its expression and intracellular localization appears to be regulated by estrogen, and down-regulation of PTa expression inhibits E 2 -induced breast cancer cell proliferation.
Materials and methods
Chemicals and materials
Cell culture media was purchased from GIBCO (Grand Island, NY, USA). Calf serum was from Hyclone Laboratories (Logan, UT, USA) and fetal calf serum from Sigma Chemical Company (St. Louis, MO, USA). 17b-Estradiol (E 2 ), trans-hyroxytamoxifen (TOT), and cycloheximide (CHX) was obtained from Sigma Chemical Company. ICI182,780 was obtained from Tocris (Ballwin, MO, USA). Custom oligonucleotides were purchased from Genosys (Grand Island, NY, USA).
Northern blot analyses
Total RNA was isolated using Trizol (GIBCO -BRL, Rockville, MD, USA). Gel purified reamplified PTa cDNA was random primer labeled using the Ready-to-Go DNA labeling kit from Pharmacia (Piscataway, NJ, USA) for Northern analysis. Twenty mg of total RNA was separated by electrophoresis, transferred to nitrocellulose support and hybridized with random primer labeled cDNA (Cho et al., 1991) . Full-length cDNA for human PTa was obtained from ATCC (Manassas, VA, USA). Quantitative analysis was performed on a Macintosh computer using the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http:// rsb.info.nih.gov/nih-image/).
Western blot analyses
Whole cell extracts were prepared from breast epithelial MCF7 cells as previously described (Wrenn and Katzenellenbogen, 1993) . Proteins were separated by electrophoresis on 15% SDS-polyacrylamide gels and transferred electrophoretically onto 0.2 micron nitrocellulose membranes. Blots were incubated with anti-PTa polyclonal antibody (1 : 2000 dilution, ImmunDiagnostik, Bensheim, Germany) and goat anti-rabbit IgG secondary antibody (1 : 30 000 dilution) for detection by chemiluminescence (Super Signal West Femto, Pierce, Rockford, IL, USA). Quantitative analysis was performed on a Macintosh computer using the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http:// rsb.info.nih.gov/nih-image/).
Plasmid construction and mutagenesis
All cloning was done using standard techniques (Ausubel et al., 1992; Sambrook et al., 1989) . The reporter vectors pPstI PTa CAT (containing the 5' regulatory region of the PTa gene from the PstI site located 75 kb from the transcriptional start site) and pApaI PTa CAT (containing the 5' regulatory region of the PTa gene from the ApaI site located 70.819 kb from the transcriptional start site) were obtained from Dr Shelby Berger (National Cancer Institute, Bethesda, MD, USA). Deletions of the pApaI PTa CAT constructs were constructed using the available restriction sites.
Reporter constructs containing fragments of the SalI/SmaI region were constructed using the following oligonucleotides with their complement: PTa (722 -680): 5'-cgcgtcgactgacttggccgacggacgccggacctgatggtgggcaa-3' PTa (679 -637): 5'-cgcgtcgaggtcgcctgcccacaggactaggggtgccctgccctggg-3' PTa (636 -594): 5'-cgcgaggggcgagggcatggcagagggacggggcggcccaggtgccc-3' Each oligonucleotide and their complement were annealed, gel purified and cloned into the MluI/XhoI-digested pCAT3 promoter vector (Promega, Madison, WI, USA). Oligonucleotides containing mutations: PTa (679 -637)mut 1: 5'-cgcgtctctagagcctgcccacaggactaggggtgccctgccctggg-3' PTa (679 -637)mut 2: 5'-cgcgtcgaggtcgcccatttgtaggactaggggtgccctgccctggg-3' PTa (679 -637)mut 3: 5'-cgcgtcgaggtcgcctgcccacagagtcgaaggtgccctgccctggg-3' PTa (679 -637)mut 4: 5'-cgcgtcgaggtcgcctgcccacaggactaggggcattttgccctggg-3' PTa (679 -637)mut 5: 5'-cgcgtcgaggtcgcctgcccacaggactaggggtgccccatttcagg-3' were annealed to their complement, gel purified, and cloned into MluI/XhoI-digested pCAT3 promoter vector. The first four nucleotides from the 5' end of the oligonucleotides were added for cloning into the pCAT3 vector.
The expression vectors for the wild type human ERa (pCMV5-ER), ERa Activation function mutant ERa DA/B , ERa DNA binding mutant ER HE82 (E203G/G204S/A207V) which changes DNA binding specificity to a GRE, and ERa Activation Function 2 mutant ER AF2mut (L540Q/E542A/ D545A) have been described previously (LeGoff et al., 1994; Montano and Katzenellenbogen, 1997; Montano et al., 1996; Wrenn and Katzenellenbogen, 1993; Mader et al., 1989) . The plasmid pCMVb (Clontech, Palo Alto, CA, USA) which encodes the b-galactosidase gene, was used as an internal control for transfection efficiency in all experiments.
Cell culture and transfections
MCF7, MDA-MB-231 and Hec-1B cells were maintained and transfected as previously described (Montano and Katzenellenbogen, 1997) . Cells were seeded for transfection in 100-mm dish in Improved Minimum Essential Media (IMEM) minus phenol red containing 5% CDCS. Cells were transfected as previously described (Montano et al., 1996) , and using 2 mg of PTa gene promoter reporter constructs, 10 ng of ERa expression vector, and 0.2 mg pCMVbgalactosidase internal control plasmid. b-galactosidase activity, which was measured to normalize for transfection efficiency, and CAT activity were assayed as previously described (Montano et al., 1996) .
Gel shift assays
Human recombinant ERa was obtained from PanVera Corp. (Madison, WI, USA). The single stranded oligomers, representing wild type and mutant PTa (679 -637) were annealed to their complement oligonucleotides. Double stranded oligomers were gel purified on a nondenaturing 4.5% polyacrylamide gel run in 16TBE. The ability of purified protein to bind to the PTa gene promoter fragments was analysed using standard gel mobility shift assays (Montano et al., 2000) . Briefly 700 fmol of recombinant ERa was mixed with 1 ng of end-labeled PTa gene oligomer in the presence of 0.4 mg/ml dIdC, 20 mM HEPES (pH 7.9), 200 mM KCl, 10 mM MgCl 2 , 2 mM DTT, 2 mM EDTA, 20% glycerol, 1 mg/ml BSA and incubated at room temperature for 20 min. The specificity of binding was assessed by competition with excess unlabeled double stranded PTa gene fragment. The presence of ERa in DNA-protein complexes was verified using supershift assays with ERa antibody, H222 (Abbott Laboratories, Chicago, IL, USA). The non-denaturing gels used to analyse the protein-DNA complexes were run as described previously (Montano et al., 2000) .
Retroviral-mediated transfection and immunostaining
Retroviruses were made by transfecting PA317 cells using the CaPO 4 coprecipitation method with the pBPSTR1 plasmid alone (to make control retroviruses) or pBPSTR1 containing PTa cDNA in the antisense orientation (Paulus et al., 1996) . PA317 media containing retroviruses was collected 48 h later and passed through a 0.45 micron filter. Breast epithelial cell lines were infected with retrovirus-containing supernatants in the presence or absence of 3 mg/ml tetracycline. When tetracycline was added, expression of the viral gene was inhibited.
PTa protein expression was examined by immunostaining using PTa antibody. Cells infected with control or antisense PTa retroviruses were grown on coverslips and subsequently fixed in 4% paraformaldehyde. After blocking with serum, samples were incubated with anti-PTa polyclonal antibody and goat, anti-rabbit IgG Alexa 488 fluorescence secondary antibody. As a negative control duplicate sections were immunostained with nonspecific rabbit IgG. Proliferating cells were identified by immunostaining using Ki67 IgG monoclonal antibody (Lab Vision) and goat, anti-mouse Alexa 594 secondary antibody (Molecular Probes). Semiquantitative analysis was performed on a Macintosh computer using Adobe Photoshop 6.0 software. Mean luminosity of 20 cells from three separate experiments was measured and averaged with background subtracted out from each field.
Proliferation assays
1610
5 cells were seeded in a 24 well plate. Two days after plating, fresh media was added containing hormones. Fresh media with hormones was added every two days. Cell number was determined five days after initial hormone treatment using the CellTiter 96 Aqueous One Solution Proliferation Assay (Promega, Madison, WI).
Abbreviations PTa, prothymosin a; ERa, Estrogen Receptor a; E 2 , estradiol; TOT, trans-hydroxytamoxifen; ERE, estrogen response element
